Raynaud's is taught as fingers turning white, then blue, then red. That sequence is hard to see on dark brown skin, so the diagnosis gets missed, and for Black adults a missed Raynaud's can mean years of lost warning before scleroderma or lupus arrives.
On this page
Raynaud's is taught with a photograph: a fingertip goes chalk white, then blue, then red. That sequence is hard to see on dark brown skin, so the condition gets missed. What you can see is a finger or toe that turns ashy, gray, or duller than the skin right next to it, then dusky or purplish, with a sharp line where the change stops. What you feel does not depend on color: numbness, pins and needles, pain, and throbbing or burning as the hand warms back up.
Why the classic description fails on dark skin
The international consensus criteria for diagnosing Raynaud's, published in the Journal of Autoimmunity in 2014, put it plainly: white pallor and blue cyanosis are the two colors necessary to make the diagnosis (PMID 24491823). Both are colors of light skin. The diagnostic standard is built around what vasospasm looks like on skin that starts out pale.
Rheumatology knows this. At the American College of Rheumatology's 2021 annual meeting, in a session on skin findings in patients of color, Lisa Zickuhr, MD, of Washington University School of Medicine told clinicians that in darker skin tones Raynaud's may look dusky rather than moving through white, blue, and red. Her wider point: the images used to teach lupus, scleroderma, and psoriasis come from patients of largely European descent.
Stop hunting for white. Look for contrast and edges:
A finger or toe that goes ashy, gray, or clearly duller than the skin above the knuckle
A dusky, slate, or purplish cast as the attack continues
A sharp demarcation line where affected skin stops and normal skin begins, which is how rheumatologists describe the change at the digits (PMID 35699336)
Timing that fits: cold air, an over-air-conditioned office, the frozen aisle at the store, or stress, reversing with warmth
Then count the symptoms that have nothing to do with color. The National Institute of Arthritis and Musculoskeletal and Skin Diseases describes the area turning cold and numb, then swelling, tingling, burning, or throbbing as circulation returns. Pain, tingling, and numbness occur independent of the visible color change (PMID 35699336). Fingers that go numb and then burn on rewarming every winter are a history worth a workup even if nobody ever saw a white finger.
What the prevalence numbers can and cannot tell you
Reported prevalence ranges from 2.1% to 22.4% across studies, a spread a 2024 review attributes to geography, ethnicity, and differing definitions (PMID 39040029). The one large US estimate specific to a Black community is a 1999 survey of 2,196 randomly selected inner-city Baltimore residents that found symptoms in 3.8% (95% CI 3.0 to 4.6). It defined a case as cold sensitivity plus a cold-induced white or blue digital color change (PMID 10360339).
That definition asks people to have noticed the exact two colors hardest to see on dark brown skin. We publish no prevalence figure for Black adults here. The research has under-enrolled Black participants and measures the condition through a visual sign that is unreliable on dark skin. Treat 3.8% as a floor, not a count.
Primary or secondary is the whole clinical point
Primary Raynaud's has no underlying cause. It is the more common form, typically starts before age 30, and does not damage the fingers. Secondary Raynaud's is vasospasm caused by something else, most often an autoimmune connective tissue disease (PMID 39040029). That distinction decides whether you get reassurance or a rheumatology referral, and how much warning you get before the underlying disease declares itself.
The red flags, and the two tests to ask for by name
A 2024 review lists the features pointing toward secondary Raynaud's: onset in adulthood rather than the teens, asymmetric involvement, digital ulcers or trophic changes on the fingertips, abnormal nailfold capillaries, and a positive ANA (PMID 39040029). A physicians' primer sets the age line from the other side: primary Raynaud's tends to develop before age 30 (PMID 35699336). New Raynaud's after about 30 earns a workup.
Two tests do most of the sorting. Name both out loud at the visit:
Nailfold capillaroscopy. A painless magnified look at the capillary loops at the base of the nail. Enlarged capillaries and capillary loss are the earliest structural signs of secondary disease.
Antinuclear antibody (ANA) testing. A blood test. A positive ANA, and more specifically a scleroderma-associated antibody, changes the risk picture.
The case for pairing them is strong. In a twenty-year prospective study of 586 people referred for Raynaud's with no definite connective tissue disease, followed for 3,197 person-years, 74 (12.6%) developed definite systemic sclerosis. Enlarged capillaries, capillary loss, and scleroderma-specific autoantibodies each independently predicted it, and people with both a capillary abnormality and an autoantibody at baseline were roughly 60 times more likely to progress (PMID 19035499). A 2024 cohort study derived and validated dedicated capillaroscopy scores for this question (PMID 38465507).
What Raynaud's can be announcing
Systemic sclerosis is the most frequent cause of secondary Raynaud's, and it may appear long before other signs and symptoms, which is what makes an early nailfold exam worth so much (PMID 35566614). A 2025 analysis of California claims data covering 11,519 people with Raynaud's and no autoimmune disease at baseline found a systemic sclerosis incidence rate of 26.15 per 1,000 person-years, against 0.08 per 1,000 in people without Raynaud's (PMID 40592552).
That matters because of what systemic sclerosis looks like when it arrives. In a series of 203 Black Americans with the disease at the University of Pittsburgh, the mean age at first symptom was 38.4 years, 51% had the diffuse cutaneous subset, 54% had pulmonary fibrosis, and 32% had severe pulmonary fibrosis (PMID 22576620). Disease that starts in your thirties and reaches the lungs in half of patients is disease where a head start changes the outcome. Our guide to scleroderma and systemic sclerosis in Black adults covers the organ screening that follows diagnosis.
Raynaud's also travels with lupus and Sjogren's, two more conditions where Black patients carry serious burden. If yours comes with joint pain, hair loss, mouth ulcers, dry eyes, dry mouth, or a rash that flares in sun, say all of it in one visit. Our guide to lupus symptoms and diagnosis in Black women covers that cluster.
What actually helps
Warm the core, not only the hands. Vasospasm responds to whole-body temperature, so layers, a hat, and warm boots do more than gloves alone. The rest of the non-drug list is short: avoid cold and emotional triggers and vibration exposure, and stop smoking (PMID 35699336).
Bring your medication list. Several common drugs constrict blood vessels and worsen attacks: beta blockers, decongestants containing pseudoephedrine, amphetamine stimulants, ergotamine, and some chemotherapy agents (PMID 39040029). Cyclosporine and interferons are on the same list (PMID 35699336). Do not stop any of them on your own. A swap is often possible.
Calcium channel blockers are the first-line drug. Nifedipine at 30 to 120 mg per day and amlodipine at 5 to 20 mg per day are the usual choices, extended-release preferred (PMID 39040029). Expect a real but modest effect. A 2017 Cochrane review of 38 trials and 982 participants found they cut attacks by about 2.93 per week once an outlier trial was excluded, against 13.7 per week on placebo, and the drop in severity was small enough that the authors flagged it as possibly not clinically meaningful (PMID 29237099). Fewer attacks, not no attacks.
How to get care, and what to bring
Do one thing first: photograph your hand during an attack, in daylight or bright white light, with an unaffected finger in the frame for comparison. The panel that wrote the consensus criteria agreed patient-provided photographs can help make the diagnosis (PMID 24491823). That photo does work a July clinic visit cannot, and it shows the demarcation line to someone trained on pale hands.
Then ask for three things by name: nailfold capillaroscopy, an ANA, and a rheumatology referral if either is abnormal or any red flag above applies. Bring the timeline, which digits are involved, whether it is symmetric, and every medication you take. To get a clinician who takes a description of ashy, dull fingers seriously the first time you say it, find a Black rheumatologist or primary care clinician in our directory.
Frequently asked questions
How do you tell if you have Raynaud's if you have dark skin?▼
Watch for a finger or toe that turns ashy, gray, or duller than the surrounding skin, then dusky or purplish, with a sharp line where the change stops. Pair that with numbness, pins and needles, pain, and throbbing or burning on rewarming. Photograph an attack in bright light with an unaffected finger in the frame.
What is the difference between primary and secondary Raynaud's?▼
Primary Raynaud's has no underlying cause, usually starts before age 30, and does not damage tissue. Secondary Raynaud's is caused by another condition, most often an autoimmune connective tissue disease, and can lead to digital ulcers. Adult onset, asymmetric involvement, fingertip ulcers, abnormal nailfold capillaries, and a positive ANA all point to secondary (PMID 39040029).
What tests should I ask for?▼
Nailfold capillaroscopy and an antinuclear antibody (ANA) blood test. In a twenty-year prospective study of 586 people with Raynaud's, enlarged capillaries, capillary loss, and scleroderma-specific autoantibodies each independently predicted progression to systemic sclerosis, and having both a capillary abnormality and an autoantibody raised that risk about 60-fold (PMID 19035499).
Can Raynaud's be the first sign of scleroderma or lupus?▼
Yes. Systemic sclerosis is one of the most frequent causes of secondary Raynaud's, and Raynaud's may appear long before any other sign of the disease (PMID 35566614). That warning window is why the nailfold exam and ANA are worth doing early instead of waiting for skin thickening or shortness of breath.
What medication is used for Raynaud's?▼
Calcium channel blockers are first-line, usually extended-release nifedipine at 30 to 120 mg per day or amlodipine at 5 to 20 mg per day (PMID 39040029). A Cochrane review of 38 trials found they cut attacks by roughly 3 per week versus placebo, with a smaller effect on severity (PMID 29237099).
Sources
Maverakis E, Patel F, Kronenberg DG, et al. International consensus criteria for the diagnosis of Raynaud's phenomenon. Journal of Autoimmunity, 2014. PMID 24491823. https://pubmed.ncbi.nlm.nih.gov/24491823/
Ramahi A, Hughes M, Khanna D. Practical management of Raynaud's phenomenon: a primer for practicing physicians. Current Opinion in Rheumatology, 2022. PMID 35699336. https://pubmed.ncbi.nlm.nih.gov/35699336/
Ture HY, Lee NY, Kim NR, Nam EJ. Raynaud's phenomenon: a current update on pathogenesis, diagnostic workup, and treatment. Vascular Specialist International, 2024. PMID 39040029. https://pubmed.ncbi.nlm.nih.gov/39040029/
Koenig M, Joyal F, Fritzler MJ, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients. Arthritis & Rheumatism, 2008. PMID 19035499. https://pubmed.ncbi.nlm.nih.gov/19035499/
Steen V, Domsic RT, Lucas M, Fertig N, Medsger TA Jr. A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis. Arthritis & Rheumatism, 2012. PMID 22576620. https://pubmed.ncbi.nlm.nih.gov/22576620/
Gelber AC, Wigley FM, Stallings RY, et al. Symptoms of Raynaud's phenomenon in an inner-city African-American community: prevalence and self-reported cardiovascular comorbidity. Journal of Clinical Epidemiology, 1999. PMID 10360339. https://pubmed.ncbi.nlm.nih.gov/10360339/
Rirash F, Tingey PC, Harding SE, et al. Calcium channel blockers for primary and secondary Raynaud's phenomenon. Cochrane Database of Systematic Reviews, 2017. PMID 29237099. https://pubmed.ncbi.nlm.nih.gov/29237099/
Maciejewska M, Sikora M, Maciejewski C, et al. Raynaud's phenomenon with focus on systemic sclerosis. Journal of Clinical Medicine, 2022. PMID 35566614. https://pubmed.ncbi.nlm.nih.gov/35566614/
Smith V, Vanhaecke A, Guerra MG, et al. Re-evaluation of nailfold capillaroscopy in discriminating primary from secondary Raynaud's phenomenon and in predicting systemic sclerosis. Expert Review of Clinical Immunology, 2024. PMID 38465507. https://pubmed.ncbi.nlm.nih.gov/38465507/
Teaw S, Shojaee A, Carnaru M, Hinchcliff M. The risk and time course for autoimmune rheumatic disease development in patients with Raynaud phenomenon. The Journal of Rheumatology, 2025. PMID 40592552. https://www.jrheum.org/content/52/10/1056
This content is for informational and educational purposes only. It is not a substitute for
professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare
provider with questions about a medical condition.
Newsletter
One email a week with essential Black health news, plus a featured provider.
